Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Stage of Development | 8 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Therapy Area | 9 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Indication | 10 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Companies | 13 | 2 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Universities/Institutes | 15 | 2 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Companies Involved in Therapeutics Development | 22 | 5 |
| AbbVie Inc. | 22 | 1 |
| Complix NV | 23 | 1 |
| Les Laboratoires Servier SAS | 24 | 1 |
| Princeton University | 25 | 1 |
| Takeda Pharmaceutical Company Limited | 26 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Drug Profiles | 27 | 16 |
| AT-101 Drug Profile | 27 | 4 |
| FL-118 Drug Profile | 31 | 2 |
| Proteins to Inhibit MCL-1 for Oncology Drug Profile | 33 | 1 |
| Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology Drug Profile | 34 | 1 |
| Small Molecule to Inhibit Mcl-1 for Cancer Drug Profile | 35 | 1 |
| Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile | 36 | 1 |
| Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile | 37 | 1 |
| Small Molecules to Inhibit MCL-1 for Breast Cancer Drug Profile | 38 | 1 |
| Small Molecules to Inhibit MCL-1 for Cancer Drug Profile | 39 | 1 |
| Small Molecules to Inhibit MCL-1 for Oncology Drug Profile | 40 | 1 |
| Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology Drug Profile | 41 | 1 |
| UMI-77 Drug Profile | 42 | 1 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Dormant Projects | 43 | 3 |
| Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Featured News &Press Releases | 46 | 13 |
| Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies | 46 | 1 |
| Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer | 46 | 2 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 48 | 1 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 49 | 1 |
| Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent | 49 | 1 |
| Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent | 50 | 1 |
| Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting | 51 | 1 |
| Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting | 51 | 2 |
| Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting | 53 | 1 |
| May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting | 54 | 1 |
| May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting | 54 | 1 |
| Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer | 54 | 2 |
| Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer | 56 | 1 |
| Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia | 56 | 1 |
| Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |